CHART Thread, page-2788

That's just ~2% of total stock so no massive meaningful short position out there for this name, plus has come way down from peak of 57m shares / ~3.80% back in early December. Shorting a stock that's down 75% peak to trough as opposed to all time highs, with two years cash funding and upcoming clinical trial results sounds like a slightly risky play to me, I mean for what level of risk-adjusted returns, guess I'm not a good shorter!